Abstract:Cancer therapy targets specific metabolic pathways or a single gene. This may result in low therapeutic effects due to drug selectivity and drug resistance. Recent studies revealed that the mitochondrial membrane potential and transmembrane permeability of cancerous mitochondria are differed from normal mitochondria. Thus, chemotherapy targeting cancerous mitochondria could be an innovative and competent strategy for cancer therapy. Previously, our work with a novel group of mitochondria targeting small molecules presented promising inhibitory capability toward various cancer cell lines and suppressed adenosine triphosphate (ATP) generation. Therefore, it is critical to understand the anticancer effect and targeting mechanism of these small molecules. This study investigated the inhibitory activity of mitochondria targeting small molecules with human cervical cancer cells - HeLa to further explore their therapeutic potential. HeLa cells were exposed to 10 mu M of syn-thesized compounds and presented elevation in intracellular reactive oxygen species (ROS) level, impaired mitochondrial membrane potential and upregulation of apoptosis as well as necrosis. In vivo, HeLa cell tumor-bearing BALB/c nude mice were treated with mitochondria targeting small molecules for 12 days consecu-tively. Throughout this chemotherapy study, no deleterious side effects nor the appearance of toxicity was observed. Furthermore, mitochondria targeting small molecules treated groups exhibited significant down-regulation with both tumor volume and tumor weight compared to the Doxorubicin (DOX) treated group. Thus, inhibition of mitochondrial ATP synthesis, activation of intracellular ROS production, down-regulation of mitochondrial membrane potential and upregulation of apoptosis and necrosis rates are the indications of cancer therapy. In this work, we examined the anticancer capability of four mitochondria targeting small molecules in vitro and in vivo, and demonstrated a novel therapeutic approach in cancer therapy with tremendous potential.

Cell-Penetrating Mitochondrion-Targeting Ligands for the Universal Delivery of Small Molecules, Proteins and Nanomaterials

Mitochondria-targeted drug delivery system for cancer treatment.

Mitochondria-targeted Drug Delivery System for Cancer Treatment

Engineered Cell-Penetrating Peptides for Mitochondrion-Targeted Drug Delivery in Cancer Therapy.

Mitochondrion-specific Dendritic Lipopeptide Liposomes for Targeted Sub-Cellular Delivery

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment

Stepwise Dual Targeting and Dual Responsive Polymer Micelles for Mitochondrion Therapy.

Targeted Delivery of Doxorubicin to Mitochondria Using Mesoporous Silica Nanoparticle Nanocarriers.

Biological Evaluation of Mitochondria Targeting Small Molecules As Potent Anticancer Drugs.

Long-Circulating Amphiphilic Doxorubicin For Tumor Mitochondria-Specific Targeting

A Mitochondria-Targeting Gold-Peptide Nanoassembly for Enhanced Cancer-Cell Killing

Delivery of Biologically Active Molecules to Mitochondria

Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy

Targeting Mitochondria Degradation by Chimeric Autophagy-Tethering Compounds

Targeting Mitochondrial Degradation by Chimeric Autophagy-Tethering Compounds.

Mitochondria Apoptosis Pathway Synergistically Activated by Hierarchical Targeted Nanoparticles Co-Delivering Sirna and Lonidamine.

Cell specific mitochondria targeted metabolic alteration for precision medicine

Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy

Mitochondrial-targeted liposome-based drug delivery – therapeutic potential and challenges

Advancements in Mitochondrial-Targeted Nanotherapeutics: Overcoming Biological Obstacles and Optimizing Drug Delivery